Compounded tirzepatide: separating real side effects from TikTok drama

What did @sonia_slays actually say?

Sonia's core story: she switched from compounded tirzepatide (from Hallandale Pharmacy) to a brand-name Mounjaro pen her husband had leftover, and says every symptom she blamed on the compound disappeared almost immediately. "The food noise is gone. I'm not hungry all the time. No side effects." She gained weight on the compound, lost it back within two brand-name pens, and is now sitting at her stated maintenance weight of 145-150 pounds. She spent $320 on the compound and calls it a waste. She's also casually floating a switch to Wegovy next month.

Worth noting upfront: she's describing a completely uncontrolled personal experience. One person, no blinding, no consistent dosing, and she used a 5 mg pen when her husband is prescribed 15 mg. That context matters a lot for what comes next.

Does the science back this up?

The honest answer is: her symptom differences are plausible but not provable from her experience alone. Compounded drugs are not required to demonstrate bioequivalence to their brand-name counterparts, and that regulatory gap is real and documented.

The FDA does not evaluate compounded drugs for efficacy or consistency before they reach patients. A 2023 analysis by Hernandez et al. in JAMA Internal Medicine noted that compounded semaglutide products showed significant variability in active ingredient concentrations across samples tested. Similar systematic data for compounded tirzepatide is sparse, but the mechanism for variability is the same: no lot-to-lot testing requirement, no bioequivalence standard.

On the flip side, the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) established tirzepatide's efficacy with the brand formulation at clinically controlled doses. If someone was getting an inconsistent dose from a compounded product, returning to a standardized pen could absolutely produce a noticeable difference. That part of her story is mechanistically coherent.

What did they get wrong (or right)?

She got the directional story right: compounded tirzepatide is not the same as Mounjaro, and the FDA has repeatedly flagged compounded GLP-1 products for quality concerns. Saying "I don't know if I got a dud batch" is actually the most accurate thing she says in the video.

What she gets wrong, or at least oversimplifies, is treating her two-pen recovery as proof the compound was defective. It might have been. Or her body may have responded differently to the brand excipients, or the timing coincided with other variables. She also used a 5 mg pen, which is a dose step, not her maintenance dose, so comparing outcomes to her husband's 15 mg experience or her prior compound dose adds more noise.

The Wegovy pivot at the end is a flag. Semaglutide and tirzepatide work differently. Tirzepatide is a dual GIP/GLP-1 agonist; semaglutide is a GLP-1 agonist only. Assuming they'll behave the same for her weight maintenance is not a safe assumption, and she should be having that conversation with a prescriber, not deciding it in a TikTok outro.

What should you actually know?

Compounded tirzepatide exists in a regulatory gray zone, and that matters. During the FDA drug shortage period, compounding pharmacies were legally permitted to produce tirzepatide copies. The FDA announced in early 2025 that tirzepatide shortages had been resolved, which changes the legal status of compounded versions going forward.

Hallandale Pharmacy, which Sonia names specifically, is a licensed 503B outsourcing facility. That's a higher regulatory tier than a standard compounding pharmacy, but it still does not require demonstrating bioequivalence to Mounjaro. A 503B facility has more oversight for sterility and quality control than a 503A compounder, but "more oversight" is not the same as "equivalent to FDA-approved drug."

If you're on a compounded GLP-1 product and having unexplained side effects, that conversation belongs with your prescriber, not a pharmacy switch you make on your own. And if you're considering switching from tirzepatide to semaglutide for maintenance, that's a clinical decision with real metabolic implications, not a try-it-and-see situation.